Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune-related pathologic response (irPR) features and immunotherapeutic response score (ITRS) predict survival following neoadjuvant/conversion combined immunotherapy in intrahepatic cholangiocarcinoma.

Virchows Archiv : an international journal of pathology·2026
Same author

DP103 as a critical modulator of Wnt signaling and cancer stemness: implications for precision treatment in triple negative breast cancer.

Cell death & disease·2026
Same author

Beyond a two-tier model: equitable molecular diagnostics for all.

BMJ oncology·2026
Same author

Integrating epigenetic and immune biomarkers to enable dynamic precision therapy in triple-negative breast cancer.

Expert review of molecular diagnostics·2026
Same author

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Science translational medicine·2026
Same author

Cancer Burden in Bangladesh: Insights From National Institute of Cancer Research & Hospital, 2014-2020.

JCO global oncology·2026

Related Experiment Video

Updated: Jun 6, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

HER2/neu revisited: quality and interpretive issues.

Syed Salahuddin Ahmed1, Jabed Iqbal, Aye Aye Thike

  • 1Department of Pathology, Singapore General Hospital, Singapore, Singapore. syed.salahuddin.ahmed@sgh.com.sg

Journal of Clinical Pathology
|December 7, 2010
PubMed
Summary

The study found excellent concordance (98.1%) between immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) for HER2/neu testing in breast cancer, meeting new quality standards.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 6, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Area of Science:

  • Oncology
  • Pathology
  • Biomarker Testing

Background:

  • Immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) are FDA-approved tests for classifying patients eligible for trastuzumab therapy.
  • Pre-analytical, analytical, and post-analytical factors can impact the accuracy of IHC and FISH testing.
  • New recommendations require at least 95% concordance between IHC and FISH for HER2/neu testing in breast cancer.

Purpose of the Study:

  • To retrospectively analyze the concordance of IHC and FISH for HER2/neu at Singapore General Hospital.
  • To investigate potential causes for disparities between IHC and FISH results.

Main Methods:

  • Retrospective review of 106 invasive ductal carcinomas evaluated for HER2/neu between 2007 and 2008.
  • Independent review of initial HER2/neu immunostained slides without knowledge of FISH results.
  • Determination of concordance between IHC and FISH assays.

Main Results:

  • Excellent concordance between IHC and FISH assays was observed (98.1%, 104/106 cases).
  • The concordance rate falls within the published range and meets new quality standards.
  • Discordant cases were attributed to known genetic heterogeneity of HER2/neu, leading to positive IHC and negative FISH results.

Conclusions:

  • The study demonstrates high concordance between IHC and FISH for HER2/neu testing.
  • The findings support the reliability of these methods in clinical practice.
  • Understanding genetic heterogeneity is crucial for interpreting discordant results.